Loading patent…
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorsWinslow S. Caughey, Byron Caughey
Estimating the term…
Methods, compounds and compositions are disclosed for treating amyloidogenic diseases, like Alzheimer's disease and type 2 diabetes, and particularly prion diseases associated with conversion of protease sensitive PrP (PrP-sen) to protease resistant PrP (PrP-res), by administering therapeutically effective amounts of a tetrapyrrole. Particular disclosed tetrapyrroles having this activity include phthalocyanines, deuteroporphyrins, and meso-substituted porphines. Complexes of certain of the pyrroles with metals or metal ions produce compounds that are particularly effective in converting the conversion of PrP-sen to PrP-sen. The treatment of the present invention is particularly suited for preventing or inhibiting the progression of prion related diseases, such as transmissible spongiform encephalopathies.
A method for inhibiting progression of an amyloidogenic disease in an animal comprising administering a therapeutically effective amount of a tetrapyrrole to the animal, the amyloidogenic disease being a disease in which the amyloid protein is AA, AL, AH, ATTR, AapoAI, Agel, Acys, AB2, Ascr, Acal, AANF or ALAPP.
The method of claim 16, wherein the tetrapyrrole is a metallophthalocyanine containing a transition metal.
A method of inhibiting the conversion of PrP-sen to PrP-res comprising contacting the PrP-sen with a tetrapyrrole.
A method for inhibiting progression of an amyloidogenic disease in an animal comprising administering a therapeutically effective amount of a tetrapyrrole to the animal, the tetrapyrrole comprising a phthalocyanine, a tetrapyrrole comprising VO or a meso-substituted porphine.
Dependencies are inferred from the claim text.